Clinical study of Gui-Shao San Umbilical Moxibustion for diarrhea-predominant Irritable Bowel Syndrome with Liver Depression and Spleen Deficiency Pattern

注册号:

Registration number:

ITMCTR2025001072

最近更新日期:

Date of Last Refreshed on:

2025-05-28

注册时间:

Date of Registration:

2025-05-28

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

桂芍散脐灸治疗肝郁脾虚型腹泻型肠易激综合征的临床研究

Public title:

Clinical study of Gui-Shao San Umbilical Moxibustion for diarrhea-predominant Irritable Bowel Syndrome with Liver Depression and Spleen Deficiency Pattern

注册题目简写:

English Acronym:

研究课题的正式科学名称:

桂芍散脐灸治疗肝郁脾虚型腹泻型肠易激综合征的临床研究

Scientific title:

Clinical study of Gui-Shao San Umbilical Moxibustion for diarrhea-predominant Irritable Bowel Syndrome with Liver Depression and Spleen Deficiency Pattern

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周梦艳

研究负责人:

章细霞

Applicant:

zhoumengyan

Study leader:

zhangxixia

申请注册联系人电话:

Applicant telephone:

13228818852

研究负责人电话:

Study leader's telephone:

13372018736

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1084831615@qq.com

研究负责人电子邮件:

Study leader's E-mail:

543013698@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市栖霞区仙林大道138号南京中医药大学

研究负责人通讯地址:

江苏省南京市红山路十字街100号江苏省中西医结合医院

Applicant address:

Nanjing University of Traditional Chinese Medicine No. 138 Xianlin Avenue Qixia District Nanjing Jiangsu Province

Study leader's address:

No. 100 Cross Street Hongshan Road Nanjing Jiangsu Province Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine

申请注册联系人邮政编码:

Applicant postcode:

210023

研究负责人邮政编码:

Study leader's postcode:

210028

申请人所在单位:

南京中医药大学护理学院

Applicant's institution:

School of Nursing Nanjing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025-LXKYZ-016

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

江苏省中西医结合医院

Name of the ethic committee:

Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/2/10 0:00:00

伦理委员会联系人:

曹晓娟

Contact Name of the ethic committee:

caoxiaojuan

伦理委员会联系地址:

江苏省南京市栖霞区红山路十字街100号江苏省中西医结合医院

Contact Address of the ethic committee:

Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine No. 100 Cross Street Hongshan Road Nanjing

伦理委员会联系人电话:

Contact phone of the ethic committee:

025-85630192

伦理委员会联系人邮箱:

Contact email of the ethic committee:

820249576@qq.com

研究实施负责(组长)单位:

江苏省中西医结合医院

Primary sponsor:

Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine

研究实施负责(组长)单位地址:

江苏省南京市红山路十字街100号江苏省中西医结合医院

Primary sponsor's address:

100 Hongshan Road Cross Street Qixia District Nanjing City Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省中西医结合医院

具体地址:

江苏省南京市栖霞区红山路十字街100号

Institution
hospital:

Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine

Address:

100 Hongshan Road Cross Street Qixia District Nanjing City Jiangsu Province

经费或物资来源:

自费

Source(s) of funding:

self-colleced

研究疾病:

肠易激综合征

研究疾病代码:

Target disease:

Irritable bowel syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

阐明桂芍散脐灸治疗肝郁脾虚型腹泻型肠易激综合征患者的临床疗效,为进一步临床推广应用提供理论依据。

Objectives of Study:

To clarify the clinical efficacy of Gui Shaosan umbilical moxibustion in the treatment of patients with liver depression and spleen deficiency diarrhea irritable bowel syndrome and to provide a theoretical basis for further clinical application.

药物成份或治疗方案详述:

采用便利抽样的方式,将在江苏省中西医结合医院消化科门诊或病房就医的符合纳排标准的腹泻型肠易激综合征患者随机分为对照组,干预组1,干预组2。对照组的患者采取口服马来酸曲美布汀胶囊的治疗,每日3次,每次1粒,共治疗4周;干预组1的患者采取口服马来酸曲美布汀胶囊外加模拟剂(每剂治疗剂量4%的生药, 加食用色素、淀粉适量)脐灸,每周2次,每次20分钟,共治疗4周;干预组2的患者采取口服马来酸曲美布汀胶囊外加桂芍散(肉桂5g、白芍15g、细辛5g、白芷10g、干姜5g、乳香10g、煨木香6g、冰片3g)脐灸,每周2次,每次20分钟,共治疗4周。于治疗首日、1周、2周、4周记录中医证候积分分级标准、中医临床症状评分、IBS-SSS评分、IBS-QOL评分、Zung焦虑、抑郁自评量表。

Description for medicine or protocol of treatment in detail:

Patients with diarrhea-type irritable bowel syndrome who met the criteria for inclusion in the outpatient clinic or ward of the Department of Gastroenterology of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine were randomly divided into control group intervention group 1 and intervention group 2. The patients in the control group were treated with oral trimebutine maleate capsules 3 times a day 1 capsule each time for a total of 4 weeks; Patients in intervention group 1 were treated with oral trimetbutine maleate capsules plus simulated agent (4% crude drug per dose plus appropriate amount of food coloring and starch) umbilical moxibustion twice a week 20 minutes each time for a total of 4 weeks; Patients in intervention group 2 were given oral trimetbutine maleate capsules plus cinnamon peony powder (cinnamon 5g white peony 15g asaroxin 5g angelica dahurica 10g dried ginger 5g frankincense 10g simmered wood fragrance 6g borneol 3g) umbilical moxibustion twice a week 20 minutes each time a total of 4 weeks. On the first day 1 week 2 weeks and 4 weeks of treatment the TCM syndrome score grading criteria TCM clinical symptom score IBS-SSS score IBS-QOL score Zung anxiety and depression self-rating scale were recorded.

纳入标准:

(1)符合IBS-D的西医诊断标准及中医肝郁脾虚证的中医辨证; (2)年龄18~59岁,意识清醒者; (3)患者知情同意并自愿参加本研究。

Inclusion criteria

(1) Meet the Western medical diagnostic criteria of IBS-D and the TCM syndrome differentiation of liver depression and spleen deficiency syndrome in TCM; (2) Age 18~59 years old conscious; (3) Patients with informed consent and voluntary participation in this study.

排除标准:

(1)合并胃肠道器质性病变如中重度消化性溃疡、糜烂、肿癌、肠上皮化生或异型增生者; (2)合并严重心脑血管、肝、肾等原发性疾病,凝血功能障碍及肿瘤患者; (3)精神病患者及严重神经官能症患者; (4)妊娠期、哺乳期或有妊娠计划的妇女; (5)纳入试验前1月内服用过抗生素或益生菌制剂或促胃肠动力药物者; (6)医嘱依从性差、不耐受艾灸的病人; (7)过敏体质和对药粉成分过敏者; (8)正在参加其他临床研究的患者。

Exclusion criteria:

(1) Patients with organic lesions of the gastrointestinal tract such as moderate to severe peptic ulcer erosion swelling cancer intestinal metaplasia or dysplasia; (2) Patients with severe cardiovascular and cerebrovascular liver kidney and other primary diseases coagulation dysfunction and tumors; (3) Psychiatric patients and patients with severe neurosis; (4) Women who are pregnant lactating or planning to become pregnant; (5) Those who have taken antibiotics or probiotic preparations or gastrointestinal prokinetic drugs within 1 month before the inclusion of the trial; (6) Patients with poor compliance with medical instructions and intolerance to moxibustion; (7) Those with allergies and allergies to the ingredients of medicinal powder; (8) Patients who are participating in other clinical studies.

研究实施时间:

Study execute time:

From 2025-01-01

To      2026-12-01

征募观察对象时间:

Recruiting time:

From 2025-02-11

To      2025-10-01

干预措施:

Interventions:

组别:

干预组1

样本量:

30

Group:

Intervention group 1

Sample size:

干预措施:

口服马来酸曲美布汀胶囊外加模拟剂脐灸

干预措施代码:

Intervention:

Oral trimetbutine maleate capsules plus mimetic umbilical moxibustion

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

口服马来酸曲美布汀胶囊

干预措施代码:

Intervention:

Oral trimeibutine maleate capsules

Intervention code:

组别:

干预组2

样本量:

30

Group:

Intervention group 2

Sample size:

干预措施:

口服马来酸曲美布汀胶囊外加桂芍散脐灸

干预措施代码:

Intervention:

Oral administration of trimeibutin maleate capsules plus Gui Shaosan umbilical moxibustion

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省中西医结合医院

单位级别:

三甲医院

Institution/hospital:

Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine

Level of the institution:

Tertiary hospital

测量指标:

Outcomes:

指标中文名:

中医证候积分分级标准

指标类型:

主要指标

Outcome:

TCM Pattern Grading Criteria

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

主要指标

Outcome:

self-rating anxiety scale(SAS)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

主要指标

Outcome:

self-rating depression scale(SDS)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医临床症状评分

指标类型:

主要指标

Outcome:

TCM Clinical Symptom Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

IBS生活质量量表评分(IBS-QOL)

指标类型:

主要指标

Outcome:

IBS Quality of Life Scale Score (IBS-QOL)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

IBS严重程度量表评分

指标类型:

主要指标

Outcome:

IBS severity scale score(IBS-SSS)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 59
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者使用SPSS24产生随机数字,得出顺序号,制作随机卡片放进外观相同、不透光信封密封。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researcher uses SPSS24 to generate random numbers obtain sequence numbers and make random cards and put them in the same appearance opaque envelope seal.

盲法:

研究生本人负责与患者沟通交流、数据收集整理及全程跟进。参与脐灸的患者在参与课题过程中对于自己接受的治疗处于未知状态。本试验中脐灸操作治疗者为消化科中医专科护士,对干预组的分组情况未知。 模拟剂及桂芍散分别贴上脾胃1号和脾胃2号的标签,干预组1使用脾胃1号进行脐灸,干预组2使用脾胃2号进行脐灸。

Blinding:

Graduate students are responsible for communicating with patients collecting and sorting data and following up the whole process. Patients who participate in umbilical moxibustion are unknown about the treatment they receive during the course of participating in the project. In this trial umbilical moxibustion was performed by TCM nurses in the Department of Gastroenterology and the grouping of the intervention group was unknown. The simulant and Gui Shaosan were labeled with Spleen and Stomach No. 1 and Spleen and Stomach No. 2 respectively and Intervention Group 1 used Spleen and Stomach No. 1 for umbilical moxibustion and Intervention Group 2 used Spleen and Stomach 2 for umbilical moxibustion.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResManl临床试验公共管理平台“http://www.medresman.org.cn/uc/index.aspx”

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan Clinical Trial Management Public Platform "http://www.medresman.org.cn/uc/index.aspx"

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)和ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF) and ResMan

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above